Adam Simpson, Icosavax CEO
December 14, 2022 10:52 AM ESTUpdated 11:11 AM
R&D

Icosavax push­es for­ward with an RSV can­di­date af­ter Covid-19 vac­cine flop

Tyler Patchen

News Reporter

Seat­tle-based Icosavax was at­tempt­ing to make a splash ear­li­er this year by show­ing off da­ta for its Covid-19 vac­cine can­di­date, but it end­ed up hit­ting …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

J&J takes 340B fight with fed­er­al gov­ern­ment to court

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times